Chiesi acquires Italian site as part of 430 million euros investment

28 March 2025

Italian biopharma Chiesi Group has announced a major investment in Nerviano, near Milan, with the building of a new facility for the production of its therapeutic solutions.

The project entails the revitalization of a historical production site, first established in 1965 as an oncology research center for Farmitalia Carlo Erba and subsequently subjected to several ownership changes, until its closure in 2024.

This facility will be primarily dedicated to manufacturing Chiesi’s carbon minimal inhalers, though dry powder inhalers and sterile biological products will also be developed at the site.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK